Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 28 April, 2020

Novo Nordisk A/S

Novo Nordisk A/S – Reduction of the share capital

Novo Nordisk A/S – Reduction of the share capital

Novo Nordisk A/S – Reduction of the share capital

Bagsværd, Denmark, 28 April 2020 – At Novo Nordisk’s Annual General Meeting on 26 March 2020, it was decided to reduce the company’s B share capital from DKK 372,512,800 to DKK 362,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 470,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 362,512,800.

The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced.
                                      

Further information

Media:    
Anne Margrethe Hauge +45 4442 3450 [email protected]
Ken Inchausti (US) +1 609 786 8316 [email protected]
     
Investors:    
Daniel Muusmann Bohsen +45 3075 2175 [email protected]
Valdemar Borum Svarrer +45 3079 0301 [email protected]
Ann Søndermølle Rendbæk +45 3075 2253 [email protected]
Mark Joseph Root +45 3079 4211 [email protected]
Kristoffer Due Berg (US) +1 609 235 2989 [email protected]


Company announcement No. 25 / 2020

Attachment


a d v e r t i s e m e n t